Abstract
Abgenix and Amgen (formerly Immunex) are developing ABX-EGF, a human monoclonal antibody against the epidermal growth factor receptor, for potential use in the treatment of cancer. ABX-EGF is undergoing phase II trials in patients with renal, colorectal, prostate and non-small-cell lung cancers. By July 2002, phase III trials for these indications were planned to start in 2003.
| Original language | English |
|---|---|
| Pages (from-to) | 541-546 |
| Number of pages | 5 |
| Journal | Current Opinion in Molecular Therapeutics |
| Volume | 5 |
| Issue number | 5 |
| Publication status | Published - Oct 2003 |
Keywords
- Animals
- adverse effects: Antibodies, Monoclonal
- metabolism: Antineoplastic Agents
- Clinical Trials, Phase I
- Clinical Trials, Phase II
- Humans
- Mice
- Mice, Transgenic
- immunology: Neoplasms
- metabolism: Receptor, Epidermal Growth Factor
